- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06203444
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
January 2, 2024 updated by: Ardelyx
This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.
Study Overview
Detailed Description
This will be an open-label study to investigate the PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.
Potential subjects will be screened to assess their eligibility to enter the study within 15 days prior to the first dose administration.
Subjects will receive tenapanor from Days 1 to 4 and will be monitored for 24 hours after the last dose of tenapanor.
On Day 4, breast milk to evaluate concentrations of tenapanor and AZ13792925 will be collected pre-dose (Hour 0), 1, 2, 4, 6, 8, and 24 hours post-dose.
Subjects will return for a Follow-up visit, 5 to 7 days (Day 10±1) after the last dose.
All breast milk not used for PK analyses will be discarded (not fed to infant) starting on Day 1 after the first dose of tenapanor is administered until Day 7 (72 hours after last dose of tenapanor).
Study Type
Interventional
Enrollment (Estimated)
7
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Susan Edelstein, PhD
- Phone Number: 510-456-7741
- Email: sedelstein@ardelyx.com
Study Contact Backup
- Name: Karishma Raju, MBBS
- Phone Number: 510-456-7728
- Email: kraju@ardelyx.com
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Recruiting
- DDSI
-
Contact:
- Lindy Kromer
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Subjects must satisfy all of the following criteria at the Screening visit unless otherwise stated:
- Females greater than or equal to 18 years of age.
- Body mass index between 18.0 and 35.0 kg/m2, inclusive.
- In good health with no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory as determined by the Investigator.
- Females must be non-pregnant.
- Has been breastfeeding or actively pumping for at least 4 weeks.
- Willing to continue regular pumping in order to maintain milk supply for the duration of the study.
- Will not feed infant breast milk while taking tenapanor and for 72 hours post the last dose of tenapanor.
- Weaning must not be underway, to ensure an adequate milk supply.
- Able to comprehend and willing to sign an ICF and to abide by the study restrictions
Exclusion Criteria:
Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:
- Significant medical or psychiatric disorder, as determined by the Investigator that would interfere with participation.
- Use or intend to use any prescription or non-prescription medications 4 days before first dose of tenapanor until Day 6 of the study, unless deemed acceptable by the Investigator and/or Sponsor.
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
- Has mastitis or other condition that would prevent the collection of milk from one or both breasts.
- Loose stools (Type 6 or 7 on the Bristol Stool Form Scale) ≥2 days in the past 7 days
- Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or 5 half-lives prior to dosing.
- Subjects who, in the opinion of the Investigator (or designee), should not participate in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
Eligible subjects will be enrolled to receive the study drug
|
The study drug will be administered in dose of 50 mg bid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of tenapanor and its major metabolite in breast milk
Time Frame: 26 Days
|
The primary objective of the study is to determine the maximum observed milk concentration (Cmax) of tenapanor and its primary metabolite AZ13792925 in the breast milk of lactating female subjects.
|
26 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The safety of tenapanor in lactating females
Time Frame: 26 Days
|
The secondary objective of the study is to assess the the incidence and severity of treatment-emergent adverse events of tenapanor when administered to lactating female subjects.
|
26 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 27, 2023
Primary Completion (Estimated)
May 8, 2024
Study Completion (Estimated)
May 8, 2024
Study Registration Dates
First Submitted
December 17, 2023
First Submitted That Met QC Criteria
January 2, 2024
First Posted (Actual)
January 12, 2024
Study Record Updates
Last Update Posted (Actual)
January 12, 2024
Last Update Submitted That Met QC Criteria
January 2, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- TEN-01-109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lactation
-
Medela AGCompleted
-
Medela AGCompleted
-
Massachusetts General HospitalCompleted
-
Chulalongkorn UniversityRecruiting
-
The Hospital for Sick ChildrenTerminated
-
Medela AGClinical Trial Unit, University Hospital Basel, SwitzerlandCompleted
-
Medical University of South CarolinaTraditional Medicinals CorporationCompletedLactationUnited States
Clinical Trials on Tenapanor
-
ArdelyxCompletedHyperphosphatemia | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
ArdelyxRecruitingIrritable Bowel Syndrome With Constipation (IBS-C)United States
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
ArdelyxEnrolling by invitationIrritable Bowel Syndrome With Constipation (IBS-C)United States
-
Kyle Staller, MD, MPHArdelyxRecruitingIBS - Irritable Bowel Syndrome | IBSUnited States
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States
-
ArdelyxAstraZenecaCompletedHealthy VolunteerUnited States
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States
-
ArdelyxCompleted
-
ArdelyxCompletedConstipation Predominant Irritable Bowel SyndromeUnited States